AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis
USA - NASDAQ:AMPH - US03209R1032 - Common Stock
26.06 USD
-0.31 (-1.18%)
26.06 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
In the past 5 years AMPH has always been profitable.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
AMPH has a Return On Assets of 8.34%. This is amongst the best in the industry. AMPH outperforms 90.58% of its industry peers.
AMPH has a Return On Equity of 17.78%. This is amongst the best in the industry. AMPH outperforms 90.58% of its industry peers.
AMPH has a Return On Invested Capital of 10.47%. This is amongst the best in the industry. AMPH outperforms 88.48% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is below the industry average of 15.35%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROIC | 10.47% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
Looking at the Profit Margin, with a value of 18.64%, AMPH belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
AMPH's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 25.14%, AMPH belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 49.86%, AMPH is in the better half of the industry, outperforming 63.35% of the companies in the same industry.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
AMPH has a better debt/assets ratio than last year.
2.2 Solvency
AMPH has an Altman-Z score of 2.52. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.52 is fine compared to the rest of the industry. AMPH outperforms 67.54% of its industry peers.
The Debt to FCF ratio of AMPH is 5.54, which is a neutral value as it means it would take AMPH, 5.54 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of AMPH (5.54) is better than 81.68% of its industry peers.
A Debt/Equity ratio of 0.80 indicates that AMPH is somewhat dependend on debt financing.
AMPH has a worse Debt to Equity ratio (0.80) than 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Altman-Z | 2.52 |
ROIC/WACC1.23
WACC8.48%
2.3 Liquidity
AMPH has a Current Ratio of 3.29. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH has a Current ratio of 3.29. This is comparable to the rest of the industry: AMPH outperforms 54.97% of its industry peers.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Quick ratio (2.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 61.62% on average per year.
Looking at the last year, AMPH shows a quite strong growth in Revenue. The Revenue has grown by 13.59% in the last year.
Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
Based on estimates for the next years, AMPH will show a small growth in Earnings Per Share. The EPS will grow by 0.50% on average per year.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.58, the valuation of AMPH can be described as very cheap.
93.72% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.89, AMPH is valued rather cheaply.
The Price/Forward Earnings ratio is 7.00, which indicates a rather cheap valuation of AMPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.24% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, AMPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.58 | ||
| Fwd PE | 7 |
4.2 Price Multiples
94.24% of the companies in the same industry are more expensive than AMPH, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 89.53% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.02 | ||
| EV/EBITDA | 6.64 |
4.3 Compensation for Growth
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
5. Dividend
5.1 Amount
AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.06
-0.31 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners71.91%
Inst Owner Change-1.06%
Ins Owners9.28%
Ins Owner Change3.46%
Market Cap1.21B
Revenue(TTM)731.97M
Net Income(TTM)134.71M
Analysts78.33
Price Target33.66 (29.16%)
Short Float %12.15%
Short Ratio10.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.06%
Min EPS beat(2)5.65%
Max EPS beat(2)12.46%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-4.74%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)11.25%
EPS beat(12)8
Avg EPS beat(12)16.86%
EPS beat(16)12
Avg EPS beat(16)21.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-1.36%
Revenue beat(4)0
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)-1.36%
Revenue beat(8)2
Avg Revenue beat(8)-1.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)9
Avg Revenue beat(16)0.92%
PT rev (1m)-0.6%
PT rev (3m)0.76%
EPS NQ rev (1m)-3.19%
EPS NQ rev (3m)0.63%
EPS NY rev (1m)-0.99%
EPS NY rev (3m)6.02%
Revenue NQ rev (1m)-1.21%
Revenue NQ rev (3m)-1.57%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)-0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.58 | ||
| Fwd PE | 7 | ||
| P/S | 1.68 | ||
| P/FCF | 11.02 | ||
| P/OCF | 7.59 | ||
| P/B | 1.6 | ||
| P/tB | 6.77 | ||
| EV/EBITDA | 6.64 |
EPS(TTM)3.44
EY13.2%
EPS(NY)3.72
Fwd EY14.29%
FCF(TTM)2.36
FCFY9.07%
OCF(TTM)3.43
OCFY13.18%
SpS15.54
BVpS16.29
TBVpS3.85
PEG (NY)N/A
PEG (5Y)0.12
Graham Number35.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.34% | ||
| ROE | 17.78% | ||
| ROCE | 12.63% | ||
| ROIC | 10.47% | ||
| ROICexc | 12.47% | ||
| ROICexgc | 23.95% | ||
| OM | 25.14% | ||
| PM (TTM) | 18.64% | ||
| GM | 49.86% | ||
| FCFM | 15.21% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 5.54 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 93.66% | ||
| Cap/Sales | 6.88% | ||
| Interest Coverage | 7.38 | ||
| Cash Conversion | 68.01% | ||
| Profit Quality | 81.61% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.52 |
F-Score5
WACC8.48%
ROIC/WACC1.23
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
EBIT growth 1Y-20.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-1.68%
EBIT Next 3Y1.08%
EBIT Next 5Y5.95%
FCF growth 1Y9.39%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y21.97%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -11.92% in the next year.